tetano
Editor, Senior Moderator
Eur J Neurol
. 2020 Aug 27.
doi: 10.1111/ene.14491. Online ahead of print.
Cytokine release syndrome-associated encephalopathy in patients with COVID-19
Peggy Perrin[SUP] 1 2 3 [/SUP], Nicolas Collongues[SUP] 2 4 5 [/SUP], Seyyid Baloglu[SUP] 6 [/SUP], Dimitri Bedo[SUP] 1 [/SUP], Xavier Bassand[SUP] 1 [/SUP], Thomas Lavaux[SUP] 7 [/SUP], Gabriela Gautier-Vargas[SUP] 1 [/SUP], Nicolas Keller[SUP] 8 [/SUP], St?phane Kremer[SUP] 6 [/SUP], Samira Fafi-Kremer[SUP] 2 3 9 [/SUP], Bruno Moulin[SUP] 1 2 3 [/SUP], Ilies Benotmane[SUP] 1 2 3 9 [/SUP], Sophie Caillard[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Background: Neurological manifestations in coronavirus disease (COVID)-2019 may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors for neurological complications. However, the lack of insight into their pathogenesis, particularly with respect to the role of the cytokine release syndrome (CRS), is currently hampering effective therapeutic interventions.
Methods: In this longitudinal study, we sought to describe the neurological manifestations of patients with COVID-19 and gain pathophysiological insights especially with respect to the CRS. Extensive clinical, laboratory, and imaging phenotyping was performed in five patients admitted to our renal unit.
Results: Neurological presentation included confusion, tremor, cerebellar ataxia, behavioral alterations, aphasia, pyramidal syndrome, coma, cranial nerve palsy, dysautonomia, and central hypothyroidism. Neurological disturbances were remarkably accompanied by laboratory evidence of CRS. SARS-CoV-2 was undetectable in the cerebrospinal fluid (CSF). Hyperalbuminorrachia and increased levels of the astroglial protein S100B were suggestive of blood-brain barrier (BBB) dysfunction. Brain MRI findings comprised evidence of acute leukoencephalitis (n = 3, of whom one with a hemorrhagic form), cytotoxic edema mimicking ischemic stroke (n = 1), or normal results (n = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted - resulting in rapid recovery from neurological disturbances in two cases. SARS-CoV2 was undetectable in 88 of the 90 patients with COVID-19 who underwent RT-PCR testing of CSF.
Conclusions: Patients with COVID-19 can develop neurological manifestations that share clinical, laboratory, and imaging similarities with those of chimeric antigen receptor-T cell-related encephalopathy. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune-mediated mechanisms.
Keywords: COVID-19; corticosteroids; cytokine; cytokine release syndrome; encephalitis; intravenous immunoglobulin; intravenous immunoglobulins; kidney; neurological disorders; neurological manifestations.
. 2020 Aug 27.
doi: 10.1111/ene.14491. Online ahead of print.
Cytokine release syndrome-associated encephalopathy in patients with COVID-19
Peggy Perrin[SUP] 1 2 3 [/SUP], Nicolas Collongues[SUP] 2 4 5 [/SUP], Seyyid Baloglu[SUP] 6 [/SUP], Dimitri Bedo[SUP] 1 [/SUP], Xavier Bassand[SUP] 1 [/SUP], Thomas Lavaux[SUP] 7 [/SUP], Gabriela Gautier-Vargas[SUP] 1 [/SUP], Nicolas Keller[SUP] 8 [/SUP], St?phane Kremer[SUP] 6 [/SUP], Samira Fafi-Kremer[SUP] 2 3 9 [/SUP], Bruno Moulin[SUP] 1 2 3 [/SUP], Ilies Benotmane[SUP] 1 2 3 9 [/SUP], Sophie Caillard[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 32853434
- DOI: 10.1111/ene.14491
Abstract
Background: Neurological manifestations in coronavirus disease (COVID)-2019 may adversely affect clinical outcomes. Severe COVID-19 and uremia are risk factors for neurological complications. However, the lack of insight into their pathogenesis, particularly with respect to the role of the cytokine release syndrome (CRS), is currently hampering effective therapeutic interventions.
Methods: In this longitudinal study, we sought to describe the neurological manifestations of patients with COVID-19 and gain pathophysiological insights especially with respect to the CRS. Extensive clinical, laboratory, and imaging phenotyping was performed in five patients admitted to our renal unit.
Results: Neurological presentation included confusion, tremor, cerebellar ataxia, behavioral alterations, aphasia, pyramidal syndrome, coma, cranial nerve palsy, dysautonomia, and central hypothyroidism. Neurological disturbances were remarkably accompanied by laboratory evidence of CRS. SARS-CoV-2 was undetectable in the cerebrospinal fluid (CSF). Hyperalbuminorrachia and increased levels of the astroglial protein S100B were suggestive of blood-brain barrier (BBB) dysfunction. Brain MRI findings comprised evidence of acute leukoencephalitis (n = 3, of whom one with a hemorrhagic form), cytotoxic edema mimicking ischemic stroke (n = 1), or normal results (n = 2). Treatment with corticosteroids and/or intravenous immunoglobulins was attempted - resulting in rapid recovery from neurological disturbances in two cases. SARS-CoV2 was undetectable in 88 of the 90 patients with COVID-19 who underwent RT-PCR testing of CSF.
Conclusions: Patients with COVID-19 can develop neurological manifestations that share clinical, laboratory, and imaging similarities with those of chimeric antigen receptor-T cell-related encephalopathy. The pathophysiological underpinnings appear to involve CRS, endothelial activation, BBB dysfunction, and immune-mediated mechanisms.
Keywords: COVID-19; corticosteroids; cytokine; cytokine release syndrome; encephalitis; intravenous immunoglobulin; intravenous immunoglobulins; kidney; neurological disorders; neurological manifestations.